Related Experiment Video
Updated: Mar 11, 2026

Intradermal Inoculation of Mycobacterium avium in the Mouse Ear
Published on: July 3, 2025
Antimicrobial Treatment of Mild Mycobacterium avium Complex Pulmonary Disease Predicted to Increase Survival and
Omri A Arbiv1, Gemma Postill2, Yunjoo Im3
1Division of Respirology, University of Toronto, Toronto, ON, Canada; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada; Clinical-Investigator Program, University of British Columbia, Vancouver, BC, Canada.
Background:
Mycobacterium avium complex pulmonary disease (MAC-PD) can lead to chronic lung disease, which can necessitate intensive antimicrobial therapy. In patients with mild MAC-PD, uncertainty exists regarding whether guideline-based antimicrobial treatment should be used as compared with watchful waiting.
Research Question:
What are the long-term consequences of initiation of antimicrobial treatment compared with watchful waiting in patients with mild MAC-PD?
Study Design And Methods:
We simulated a cohort of 70-year-old Canadian individuals with nodular bronchiectatic MAC-PD with a macrolide-susceptible specimen and normal lung function. We used a lifetime model to compare guideline-based treatment with observation for patients with MAC-PD, accounting for common adverse events, culture conversion rates, and disease recurrences from prior literature. Our outcomes were quality-adjusted life years (QALYs) and life years. The primary analysis was a probabilistic Monte Carlo simulation to estimate the mean and 95% uncertainty intervals (UIs) for each outcome under treatment and observation, as well as the treatment to observation difference. Additional outcomes included deterministic analysis and 1-way and 2-way deterministic sensitivity analyses.
Results:
In the primary analysis, the cohort of individuals receiving antimicrobial treatment showed a mean of 15.9 QALYs (95% UI, 12.4-19.3 QALYs), whereas those under observation showed 13.4 QALYs (95% UI, 9.0-16.4 QALYs), with a treatment to observation difference of 2.5 QALYs (95% UI, 0.8-4.7 QALYs). Similarly, those receiving treatment showed a mean 18.3 life years (95% UI, 19.2-25.5 life years), and those under observation showed 15.8 life years (95% UI, 17.3-22.2 life years). The treatment to observation difference was 2.5 years (95% UI, 1.0-4.2 years). Increase in QALYs and life years was consistent across almost all sensitivity analyses.
Interpretation:
In a simulated cohort, guideline-based treatment increased QALYs and life years in patients with mild MAC-PD. Our findings can support patients and physicians in deciding on treatment approach.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation

